# A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

Source: https://onco.cc/trials/nct07751991/  
OnCo record `nct07751991` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CHM-029 run by Charm Therapeutics, now recruiting.

## Summary

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML is a phase 1 interventional study registered as NCT07751991 by Charm Therapeutics, with 40 participants planned, started 2026-09-28. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CHM-029.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07751991
- Phase: 1
- Setting: A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements
- Sponsor: Charm Therapeutics
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07751991: https://clinicaltrials.gov/study/NCT07751991

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [CHM-029](https://onco.cc/drugs/chm-029/)
- companies: [CHARM Therapeutics](https://onco.cc/companies/charm-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07751991.json